検索結果

千寿製薬株式会社

NEWS & RELEASE December 22, 2025 Obtained manufacturing and marketing approval in Japan for Avarept® Ophthalmic suspension 0.3%, a novel treatment of Dry Eye Disease through Transient Receptor Pot...

Data And Statistics | About Senju | SENJU Pharmaceutical

6% 2.2 4.7% 2.6 5.5% 2.8 5.7% Overseas Business 5.1 12.5% 6.4 15.8% 8.1 17.5% 9.9 20.3% 10.9 22.4% Others 0.5 1.2% 2.0 5.0% 2.0 4.4% 2.2 4.7% 1.4 2.9% ＊A new accounting standard for revenue recognitio...

发表论文 | 研究与开发 | 千寿制药株式会社

zed, Double-Masked, Dose-Finding Study Yuichi Hori1, Tomoyuki Wada2, Kazunori Omatsu2, on behalf of the SJP-0132 clinical study investigators 1: Department of Ophthalmology, Toho University Faculty of...

で失明の主 な原因となっています 8。日本では、約 10 万人が罹患していると推定されており、これまでに承認された治療法はありません でした 2,3。 参考文献 1 Boyer DS, et al. The pathophysiology of geographic atrophy secondary to age-related macular degeneration and the comp...

Presence of Products | Overseas Activities | SENJU Pharmaceutical

Name Marketing Authorisation Holder JP Brand Name YELLOX Bausch + Lomb Poland Sp. z o.o. BRONUCK Netherland Brand Name Marketing Authorisation Holder JP Brand Name YELLOX Bausch + Lomb Poland Sp. z o...